Is semaglutide a better weight-management option than bariatric surgery for patients undergoing total knee arthroplasty? Journal Abstract - Guideline Central

Is semaglutide a better weight-management option than bariatric surgery for patients undergoing total knee arthroplasty?

Published: 2026 Feb 20

Authors

, , , , ,

Abstract

BACKGROUND: Bariatric surgery has been associated with increased risks of revision surgery following total knee arthroplasty (TKA), raising concerns about its safety for weight management in this population. Semaglutide, a glucagon-like peptide-1 receptor agonist, has emerged as a promising pharmacologic alternative, though its impact on TKA outcomes remains underexplored. This study compares TKA outcomes between patients who have a history of bariatric surgery and semaglutide use. METHODS: A retrospective analysis of 19,135 TKA patients from 2012 to 2023 identified three cohorts: patients who used semaglutide (SU, n = 402), had bariatric surgery (BS, n = 418), and a BMI > 35 control group (C, n = 6,650). Demographics, BMI trends, 90-day complications, and revision rates were compared using statistical analyses, including Kaplan-Meier survivorship and multivariate logistic regression. RESULTS: Bariatric surgery patients experienced significantly more 90-day emergency department (ED) visits (7.9 [BS] vs. 5.7 [SU] vs. 4.0% [C], P < 0.001) and lower 10-year implant survival (90.3 [BS] vs. 94.5% [C], P = 0.039). Multivariate analysis demonstrated that a history of BS independently predicted increased odds of ED visits (OR 1.79, P = 0.005) and revision (OR 1.71, P = 0.028), while SU was not a significant predictor of adverse outcomes. The BS group achieved the largest preoperative BMI reduction (–1.8 kg/m²) vs. SU (–0.7 kg/m²) and controls (+ 2.1 kg/m²). Notably, the SU cohort regained 1.7 kg/m² within three years post-TKA. CONCLUSION: While semaglutide use before TKA was associated with only modest weight loss, it appeared safe and yielded favorable short-term outcomes. Bariatric surgery, though more effective for weight reduction, carried higher complication rates and inferior long-term implant survivorship. Further research is needed to clarify semaglutide’s long-term role in TKA patients with obesity. LEVEL OF EVIDENCE: III.

Keywords: Bariatric surgery, GLP-1 receptor agonist, Obesity, Semaglutide, Survivorship, Total knee arthroplasty

Source

Archives of orthopaedic and trauma surgery

Publication Type

Journal Article

Language

English

PubMed ID

41718773

MeSH terms

You rely on Guideline Central for transparency

Guideline Central and select third party use “cookies” on this website to enhance the user experience.

This technology helps us gather statistical and analytical information to optimize the relevant content for you.

The user also has the option to opt-out which may have an effect on the browsing experience.